Regulatory Sourcebook eBook
Read the article:
Collecting Industry’s Thoughts on FDA FARS Report
Read the ebook:
BioPharm International’s Regulatory Sourcebook eBook
Industry representatives sound off on FDA’s FARS report, released in January this year.
gorynvd/Stock.adobe.com
FDA’s January 2021 release of its Focus Areas of Regulatory Science (FARS) report outlines topics that need continued targeted investment to advance regulatory science research that can facilitate the development of innovative products. The report also outlines the agency’s needs for data provision and methodology clarification to inform its regulatory decision-making process in the hopes that this will improve guidance for sponsors. Representatives from Bio-Process Systems Alliance and BioPhorum shared their thoughts on the report and provided feedback from an industry perspective.
Read this article in BioPharm International’s October 2021 Regulatory Sourcebook eBook.
Read the article:
Collecting Industry’s Thoughts on FDA FARS Report
Read the ebook:
BioPharm International’s Regulatory Sourcebook eBook
Feliza Mirasol is the science editor for BioPharm International.
BioPharm International
eBook: Regulatory Sourcebook, October 2021
October 2021
Pages: 4–5
When referring to this article, please cite it as F. Mirasol, “Collecting Industry’s Thoughts on FDA FARS Report," BioPharm International Regulatory Sourcebook eBook (October 2021).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.